Black Diamond Therapeutics
BDTX
111 hedge funds and large institutions have $71.3M invested in Black Diamond Therapeutics in 2026 Q3 according to their latest regulatory filings, with 25 funds opening new positions, 38 increasing their positions, 27 reducing their positions, and 10 closing their positions.
150% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 10
90% more capital inflows, than outflows
Capital inflows: $11.6M | Capital outflows: $6.12M
41% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 27
16% more funds holding
Funds holding: 96 → 111 (+15)
4.7% more ownership
Funds ownership: 61.17% → 65.87% (+4.7%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$3.2M |
| 2 |
AQR Capital Management
Greenwich,
Connecticut
|
+$1.74M |
| 3 |
Morgan Stanley
New York
|
+$1.07M |
| 4 |
State Street
Boston,
Massachusetts
|
+$819K |
| 5 |
Goldman Sachs
New York
|
+$781K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Balyasny Asset Management
Chicago,
Illinois
|
-$891K |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
-$802K |
| 3 |
AIC
AWM Investment Company
New York
|
-$685K |
| 4 |
Renaissance Technologies
New York
|
-$608K |
| 5 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$491K |
BDTX Hedge Fund Activity: Q3 2026 in Review
111 of the 8,227 institutional investors tracked by Wall St. Rank reported a position in Black Diamond Therapeutics (BDTX) for Q3 2026, worth a combined $71.3M — up 9.9% from $64.9M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new BDTX positions and 10 closed out — a net gain of 15 holders — while 38 added to existing stakes and 27 trimmed.
The largest buyer was Bank of America, adding an estimated $3.2M. The largest seller was Balyasny Asset Management, cutting an estimated $891K.
- 111 institutional investors held Black Diamond Therapeutics (BDTX) as of Q3 2026, up from 96 in Q2 2026.
- Funds reported $71.3M of Black Diamond Therapeutics stock for Q3 2026, up 9.9% quarter-over-quarter.
- 25 funds opened new Black Diamond Therapeutics positions in Q3 2026 and 10 closed out, a net change of +15 holders.
- The largest Black Diamond Therapeutics buyer in Q3 2026 was Bank of America, an estimated $3.2M added.
- The largest Black Diamond Therapeutics seller in Q3 2026 was Balyasny Asset Management, an estimated $891K sold.
Based on aggregated 13F filings for Q3 2026.